<DOC>
	<DOCNO>NCT02743923</DOCNO>
	<brief_summary>The purpose study determine whether carboplatin-paclitaxel-bevacizumab result prolong progression free survival compare cisplatin-pemetrexed first line treatment patient KRAS mutate non-small cell lung cancer .</brief_summary>
	<brief_title>Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab KRAS Mutated Non-small Cell Lung Cancer</brief_title>
	<detailed_description>KRAS mutation occur 30 % patient non-small cell lung cancer , especially adenocarcinoma . For long time KRAS mutation relate poor prognosis poor response chemotherapy . Recent data however show true . It seem response , progression free survival overall survival similar KRAS mutate . Until specific targeted therapy available KRAS mutate NSCLC patient . Optimization treatment advance NSCLC patient KRAS mutation could also achieve select best available chemotherapy treatment . Two standard chemotherapy scheme frequently use FDA EMA approve first line treatment patient adenocarcinoma : cisplatin-pemetrexed carboplatin-paclitaxel-bevacizumab . The aim randomize phase III study compare two standard treatment regimens patient KRAS mutate , advanced stage NSCLC hypothesis bevacizumab chemotherapy improve outcome compare chemotherapy alone first line treatment . Furthermore outcome different KRAS mutation study . Treatment one two follow chemotherapy combination accord label : carboplatin-paclitaxel-bevacizumab cisplatin-pemetrexed q3wks six cycle . Continuation maintenance bevacizumab pemetrexed allow progression . Blood archival tissue optionally collect translational research . This may help identify subgroups patient likely well treat specific treatment regimen .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Histologically cytologically confirm ( nonsquamous ) NSCLC incurable locally advanced metastatic ( stage IIIB stage IV ) disease . 2 . Documented KRAS mutation 3 . Chemotherapynaive NSCLC patient . Adjuvant chemotherapy chemoradiotherapy allow give &gt; 1 year study entry . 4 . At least one unidimensionally measurable lesion meeting RECIST1.1 . 5 . ECOG PS 02 6 . Age ≥ 18 year 7 . Adequate organ function , include : Adequate bone marrow reserve : ANC ≥ 1.5 x 109/L , platelet ≥ 100 x 109/L . Hepatic : bilirubin ≤1.5 x ULN , AP , ALT , AST ≤ 3.0 x ULN AP , ALT , AST ≤5 xULN acceptable liver tumor involvement Renal : calculated creatinine clearance ≥ 60 ml/min base CockroftGault formula . Urine protein ( dipstick ) &lt; 2 + ; ≥ 2 + : 24 hour urine protein ≤ 1 gr . 8 . Signed informed consent 9 . Male female patient reproductive potential must use approved contraceptive method , appropriate . Female patient childbearing potential must negative serum pregnancy test within 7 day prior study enrollment . 1 . Pregnant lactate woman 2 . Clinically significant ( i.e . active ) cardiovascular disease : congestive heart failure &gt; NYHA class 2 ; CVA myocardial infarction &lt; 6 month prior study entry ; uncontrolled hypertension ( blood pressure systolic &gt; 150 mmHg and/or diastolic &gt; 100 mmHg ) 3 . History hemoptysis ≥ grade 2 ( bright red blood least 2,5 ml last 3 month ) 4 . Evidence tumor invade major blood vessel image ( i.e . superior vena cava pulmonary artery ) 5 . Patients evidence history bleed diathesis 6 . Nonhealing wound ulcer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>